Open Access Research
, Hayder Abdul-Amir Al-Hindy1,*, Amir Saheb Al-Mumin21College of Pharmacy, University of Babylon, Hillah, Iraq2Hammurabi Medical College, University of Babylon, Hillah, Iraq
*Corresponding author: Hayder Abdul-Amir Al-Hindy, College of Pharmacy, University of Babylon, Hillah, Iraq
Tel.: +964-(0)7708020200
E-mail: phar.hayder.abdul@uobabylon.edu.iq
Download PDF
Published: 5 May 2024; https://doi.org/10.61873/HHPT2430
Abstract
Cystatin C (CysC) levels in patients with multiple myeloma (MM) have been linked to tumour load and outcomes’ prediction. This study aimed at assessing the diagnostic utility of CysC in distinguishing MM patients from controls and advanced stages of MM. In total, 98 MM patients and 57 healthy controls participated in this cross-sectional case-control study. Demographic, clinical, and biochemical data were assessed. The study groups exhibited significantly diverse measures of urea, creatinine, CysC, β2-microglobulin, and lactate dehydrogenase activity. β2-Microglobulin was found to be a reliable predictor for both the MM staging and its diagnosis, but CysC was found to only possess a partial capacity of predicting advanced MM stages. Our results highlight the significance of taking into account many biomarkers in the therapy of MM, so as to achieve effective clinical evaluation. More research is required in order to clarify the CysC implication in the prognosis and management of MM.
Keywords: multiple myeloma, LDH, β2-microglobulin, staging, cystatin C
Please cite as:
Mousa M. J., Al-Hindy H. A. A., Al-Mumin A. S. Evaluation of serum cystatin C levels in multiple myeloma: diagnostic significance and clinical implications. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38 (Sup2): 145-148 (2024). https://doi.org/10.61873/HHPT2430